Last reviewed · How we verify

Giant cell arteritis in adults — Treatment Landscape & Competitive Intelligence

Giant cell arteritis in adults (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Giant cell arteritis in adults, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Rinvoq upadacitinib AbbVie Inc. JAK inhibitor Janus kinase (JAK) enzymes, particularly JAK1 and JAK2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. AbbVie Inc. · 1 drug in Giant cell arteritis in adults

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Giant cell arteritis in adults:

Cite this brief

Drug Landscape (2026). Giant cell arteritis in adults — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/giant-cell-arteritis-in-adults. Accessed 2026-06-11.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing